Key advances
-
Non-invasive plasma proteomics from patients with alcohol-related liver disease (ALD) can be used to identify prognostic biomarkers and potential targets for therapy5.
-
The gut–liver axis has a key role in the pathophysiology of ALD; the complement receptor of immunoglobulin superfamily (CRIg) mediates pathogen recognition and phagocytic function in ALD and could represent a novel targeted therapy7.
-
Early liver transplantation for patients with severe alcohol-associated hepatitis not responding to medical therapy provides a significant survival benefit; although there is a slightly higher risk of relapse after liver transplantation, clinical outcomes at 2 years are similar in early versus standard liver transplantation indication in patients with ALD9.
In 2022, we witnessed advances in the field of alcohol-related liver disease. Key developments included the discovery of novel proteomics-based biomarkers and potential therapeutic targets that regulate the recognition of molecules derived from gut microbiota to modulate liver injury. Additionally, there have been significant advances in refining selection for liver transplantation in severe alcohol-associated hepatitis.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ayares, G. et al. Public health measures and prevention of alcohol-associated liver disease. J. Clin. Exp. Hepatol. 12, 1480–1491 (2022).
Griswold, M. G. et al. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 392, 1015–1035 (2018).
Kwong, A. J. et al. OPTN/SRTR 2020 Annual Data Report: Liver. Am. J. Transplant 22 (Suppl. 2), 204–309 (2022).
Arab, J. P. et al. Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: a worldwide study. J. Hepatol. 75, 1026–1033 (2021).
Niu, L. et al. Noninvasive proteomic biomarkers for alcohol-related liver disease. Nat. Med. 28, 1277–1287 (2022).
Duan, Y. et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 575, 505–511 (2019).
Duan, Y. et al. CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease. Nat. Commun. 12, 7172 (2021).
Mathurin, P. et al. Early liver transplantation for severe alcoholic hepatitis. N. Engl. J. Med. 365, 1790–1800 (2011).
Louvet, A. et al. Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study. Lancet Gastroenterol. Hepatol. 7, 416–425 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Arab, J.P., Bataller, R. Advancing alcohol-related liver disease: from novel biomarkers to refining selection for liver transplantation. Nat Rev Gastroenterol Hepatol 20, 71–72 (2023). https://doi.org/10.1038/s41575-022-00723-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-022-00723-6